Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Baylor College of Medicine |
---|---|
Information provided by: | Baylor College of Medicine |
ClinicalTrials.gov Identifier: | NCT00691600 |
The purpose of this study is to compare successful rates of cure of abscesses less than 5 cm with antibiotic versus non-antibiotic treatment after incision and drainage. We will also compare successful rates of cure and time to healing with IV antibiotics and 23-hour observation unit stay versus hospitalization with IV antibiotics for abscesses greater than 5 cm but less than 10 cm in pediatric patients.
Condition | Intervention | Phase |
---|---|---|
Abscess |
Drug: oral trimethoprim/sulfamethoxazole Drug: Placebo Other: Observational Unit Short Stay Other: Hospitalization |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Single Group Assignment, Efficacy Study |
Official Title: | Phase 3 Study Comparing Bactrim to Placebo in the Management of Abscesses < 5cm and 23 hr Observation Unit to Inpatient Treatment in the Management of Abscesses 5-10cm in the Pediatric Population. |
Estimated Enrollment: | 472 |
Study Start Date: | December 2007 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
TMP/SMX vs Placebo: Placebo Comparator
subjects with abscesses less than 5cm will be randomized to either study med or placebo
|
Drug: oral trimethoprim/sulfamethoxazole
80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
Drug: Placebo
Placebo caps or suspension every 12 hours for 10 days
|
Hospitalization vs. 23 HR OBS Unit
Patients with abscesses 5-10cm will be randomized to either inpatient stay or 23 hour short stay in the observation unit.
|
Other: Observational Unit Short Stay
Patients with abscesses greater that 5cm to 10cm randomized to Observational Short Stay unit for up to 23 hrs.
Other: Hospitalization
Patients with abscesses 5-10cm may be randomized to inpatient treatment
|
Ages Eligible for Study: | 90 Days to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
Texas Children's Hospital | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Brian Schultz, MD 832-824-5497 schultz@bcm.edu | |
Contact: Troy Bush, BS 832-824-2246 tbush@bcm.edu | |
Principal Investigator: Charles G Macias, MD, MPH | |
Sub-Investigator: Brian Schultz, MD |
Responsible Party: | Baylor College of Medicine ( Charles Macias, MD, MPH ) |
Study ID Numbers: | H-18758 |
Study First Received: | December 28, 2007 |
Last Updated: | June 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00691600 |
Health Authority: | United States: Institutional Review Board |
abscess Abscesses in the pediatric emergency population |
Folic Acid Trimethoprim Sulfamethoxazole Abscess |
Suppuration Emergencies Trimethoprim-Sulfamethoxazole Combination Inflammation |
Anti-Infective Agents Antiprotozoal Agents Molecular Mechanisms of Pharmacological Action Anti-Infective Agents, Urinary Enzyme Inhibitors Infection Renal Agents |
Folic Acid Antagonists Pharmacologic Actions Antimalarials Antiparasitic Agents Pathologic Processes Therapeutic Uses |